NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
|
a.
|
General:
NanoVibronix Inc. (“the Company”), a Delaware corporation, commenced operations on October 20, 2003 and
is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain
therapy and can be administered at home, without the assistance of medical professionals.
|
The
Company’s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix Ltd., a company registered in Israel, which also commenced operations in October 2003.
|
b.
|
Going concern, liquidity and capital resources:
The
Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products
and the receipt of additional financing until profitability is achieved. The Company has incurred losses in the amount of
$4,154 during the year ended December 31, 2018, has an accumulated deficit of $32,536 as of December 31, 2018 and has negative cash flow from operating activities that amounted to $ 3,550 for the year ended December 31, 2018.
The Company expects
to continue incurring losses and negative flows from operations. As a result, the Company will not have sufficient resources
to fund its operations for the next twelve months. These conditions raise substantial doubts about the Company’s ability
to continue as a going concern for a period within the year after the issuance of these financial statements.
During the next twelve months management expects that the Company will need to raise additional
capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital
raising as long as its products do not reach commercial profitability. Management’s plans include the continued commercialization
of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows
from strategic partnerships. There are no assurances, however, that the Company will be successful in obtaining the level
of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital,
it will need to reduce activities, curtail or cease operations. The financial statements do not include any adjustments with
respect to the carrying amounts of assets and liabilities and their classification that might be necessary should the Company
be unable to continue as a going concern.
|
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES
|
The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States (“U.S. GAAP”).
The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments
and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based
upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the
reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts
in thousands (except share and per share data)
|
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
|
b.
|
Principles
of consolidation:
|
The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, NanoVibronix (Israel 2003)
Ltd. All intercompany balances and transactions have been eliminated upon consolidation.
|
c.
|
Foreign currency translation and transaction
|
Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All transaction gains and losses from
re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of
operations as financial income or expenses, as appropriate.
Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months
or less at acquisition.
Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary
course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the
“first-in, first-out” method.
Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically
evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume.
Based on this evaluation, provisions are made when required to write-down inventory to its net market value.
|
f.
|
Property
and equipment:
|
Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets, at the following annual rates:
|
|
Years
|
|
|
|
|
|
Computers
and peripheral equipment
|
|
|
3
|
|
Office
furniture and equipment
|
|
|
5-7
|
|
|
g
.
|
Impairment
of long-lived assets:
|
The
Company’s long-lived assets are reviewed for impairment in accordance with Accounting Standard Codification (“ASC”)
360, “Property, Plant, and Equipment”, whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount
of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be
impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. During the years ended December 31, 2018 and 2017, no impairment losses have been identified.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
The
Company’s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law
based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date,
and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases
of insurance policies. The value of these deposits and policies is recorded as an asset in the Company’s balance sheet.
Severance
expenses for the years ended December 31, 2018 and 2017 amounted to $ 46 and $ 85, respectively.
The
Company accounts for stock warrants
held by investors
as either equity instruments or liabilities in accordance with ASC 480,
Distinguishing
Liabilities from Equity
(“ASC 480”), depending on the specific terms of the warrant agreement.
Stock
warrants are accounted for as a liability if they contain “down-round protection” or other terms that could potentially
require “net cash settlement”
in accordance
with the provisions of ASC 815-40,
Derivatives and Hedging - Contracts in Entity’s Own Equity
(“ASC 815”),
which provides a two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed
to an issuer’s own stock and thus able to qualify to be a derivative financial instrument. The Company measures such warrants
at fair value by applying the Black-Scholes option pricing model in each reporting period until they are exercised or expired,
with changes in the fair value being recognized in the Company’s statement of comprehensive loss as financial income or
expense, as appropriate.
|
k.
|
Debt
Issued with Warrants:
|
The
Company considers guidance within ASC 470-20, Debt (ASC 470), ASC 480, and ASC 815 when accounting for the issuance of convertible
debt with detachable warrants. As described above under the caption “Warrants”, the Company classifies stock warrants
as either equity instruments or liabilities depending on the specific terms of the warrant agreement. In circumstances in which
debt is issued with liability-classified warrants, the proceeds from the issuance of convertible debt are first allocated to the
warrants at their full estimated fair value and established as both a liability and a debt discount. The remaining proceeds, as
further reduced by discounts created by the bifurcation of embedded derivatives and a beneficial conversion feature, is allocated
to the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount
from the allocation of proceeds, to interest expense using the effective interest method over the expected term of the debt instrument
pursuant to ASC 835, Interest (ASC 835).
The
Company applied ASC 470-20 and ASC 815 to the Convertible promissory notes (see Note 7).
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts
in thousands (except share and per share data)
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
The
Company generates revenues from the sale of its products to distributors and patients. For the year ended December 31, 2018,
revenues from those products are recognized in accordance with ASC 606 ,
Revenue from Contracts with Customers,
whose core principle is to recognize revenues when promised goods or services are transferred to customers in an amount that
reflects the consideration that is expected to be received for those goods or services.
During the year ending December 31, 2017, revenues were recognized in accordance with ASC 605, “Revenue
Recognition,” when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed or determinable, no
further obligation exists and collectability is probable.
Revenues
from sales to distributors are recognized at the time the products are shipped to the distributors (“sell-in”).
The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.
|
m.
|
Research
and development costs:
|
Research
and development costs are charged to the statement of operations, as incurred.
The
Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the
liability method whereby deferred tax assets and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect
when the differences are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to
the amount that is more likely than not to be realized.
In
November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, related to balance sheet classification
of deferred taxes. The ASU requires that deferred tax assets and liabilities be classified as noncurrent in the statement of financial
position, thereby simplifying the current guidance that requires an entity to separate deferred assets and liabilities into current
and noncurrent amounts. ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15,
2017 and interim periods within those annual periods. ASU 2015-17 was adopted by the Company as of January 1, 2018, and
had no impact on its consolidated financial statements.
The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax
position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is
more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution
of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more
than 50% (cumulative basis) likely to be realized upon ultimate settlement.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts
in thousands (except share and per share data)
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
The
Company accounts for stock-based compensation in accordance with ASC 718, “Compensation - Stock Compensation”, (“ASC
718”), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an
option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over
the requisite service periods on a straight line method in the Company’s consolidated statement of operations.
The
Company has early adopted ASU 2017-09 in the 2017 consolidated financial statements using a modified retrospective transition
method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted.
As a result of this adoption, the Company recorded an increase to accumulated deficit of $11 resulting from the election of accounting
policy to account for forfeitures as they occur as of January 1, 2017.
The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options
awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price
volatility and the expected option term. Expected volatility was calculated based upon similar traded companies’ historical
share price movements. The expected option term represents the period that the Company’s stock options are expected to be
outstanding. The Company currently uses the simplified method and will continue to do so until sufficient historical exercise
data supports using expected life assumptions. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon
bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and
expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to
pay cash dividends in the future.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts
in thousands (except share and per share data)
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
|
p.
|
Fair
value of financial instruments:
|
ASC
820, “Fair Value Measurements and Disclosures,” defines fair value as the price that would be received to sell an
asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants
at the measurement date.
In
determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring
fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most
observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset
or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that
reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.
The
hierarchy is broken down into three levels based on the inputs as follows:
|
Level
1 -
|
Valuations
based on quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access at the
measurement date.
|
|
Level
2 -
|
Valuations
based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either
directly or indirectly.
|
|
Level
3 -
|
Valuations
based on inputs that are unobservable and significant to the overall fair value measurement.
|
The
carrying amounts of cash and cash equivalents, trade receivables, prepaid expenses and other accounts receivable, trade payables
and other accounts payables approximate their fair value due to the short-term maturities of such instruments.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts
in thousands (except share and per share data)
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
|
q.
|
Basic
and diluted net loss per share:
|
Basic
net loss per share is computed based on the weighted average number of shares of Common stock, Preferred C and Preferred D stock
outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares of Common
stock, Preferred C and Preferred D stock outstanding during each year plus dilutive potential equivalent shares of Common stock,
Preferred C and Preferred D stock considered outstanding during the year, in accordance with ASC 260, “Earnings per Share.”
For
the years ended December 31, 2018 and 2017, all outstanding stock options and warrants have been excluded from the calculation
of the diluted net loss per share as all such securities are anti-dilutive for all years presented.
|
r.
|
Concentrations
of credit risk:
|
Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.
Cash and cash equivalents are invested in major banks in U.S. and Israel. Management believes that the financial institutions
that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these
investments.
The
Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign
hedging arrangements.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts
in thousands (except share and per share data)
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
|
s.
|
Impact
of recently issued accounting standards:
|
|
|
|
|
In May 2014, the Financial Accounting
Standards Board (FASB), issued Accounting Standards Update (ASU) 2014-09,
Revenue from Contracts with Customers (ASC 606)
,
to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues
when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be
received for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so,
it is possible more judgment and estimates may be required within the revenue recognition process than are required under existing
GAAP, including identifying performance obligations in a contract, estimating the amount of variable consideration to include in
the transaction price and allocating the transaction price to each separate performance obligation. The Company has early adopted
the new revenue standard as of January 1, 2018, using a modified retrospective adoption transition to each prior reporting period
presented. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date.
Revenue Recognition
Generally the Company considers all revenues
as arising from contracts with customers. Revenue is recognized based on the five step process outlined in ASC606:
Step 1 – Identify the Contract
with the Customer
– A contract exists when (a) the parties to the contract have approved the contract and are committed
to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services
to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract
has commercial substance and (e) it is probably that the entity will collect substantially all of the consideration to which it
will be entitled in exchange for the goods or services that will be transferred to the customer.
Step 2 – Identify Performance
Obligations in the Contract
– Upon execution of a contract, the Company identifies as performance obligations each promise
to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are
substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised
goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within
the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation.
Step 3 – Determine the Transaction
Price
– When (or as) a performance obligation is satisfied, the Company shall recognize as revenue the amount of the
transaction price that is allocated to the performance obligation. The contract terms are used to determine the transaction price.
Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine
the amount of variable consideration that should be included in the transaction price based on expected value method. Variable
consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant
future reversal of cumulative revenue under the contract would not occur.
Step 4 – Allocate the Transaction
Price
– After the transaction price has been determined, the next step is to allocate the transaction price to each performance
obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to
that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations
based on the relative standalone selling price (SSP) at contract inception.
Step 5 – Satisfaction of the Performance
Obligations (and Recognize Revenue)
– When an asset is transferred and the customer obtains control of the asset (or
the services are rendered), the Company recognizes revenue. At contract inception, the Company determines if each performance obligation
is satisfied at a point in time or over time. For device sales, revenue is recognized at a point in time when the goods are transferred
to the customer and they obtain control of the asset. For maintenance contracts, revenue is recognized over time as the performance
obligations in the contracts are completed.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
2:-
|
SIGNIFICANT
ACCOUNTING POLICIES (Cont.)
|
Product
sales
The
Company sells its products through distributors and directly to patients. Under ASC 606, revenue from product sales
is recognized at the point in time when the shipment is made and when title and risk of loss transfers to these customers.
Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration for
customer rights of return using an expected value method. Amounts of variable consideration are included in the transaction
price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not
occur when the uncertainty associated with the variable consideration is subsequently resolved. Product sales are recorded
net of estimated product returns and other deductions. The Company’s adoption of ASC 606 did not have a material
impact on the Company’s financial statement.
Recently
issued accounting standards
In
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities
that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments
(the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. For leases
with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not
to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases
at the beginning of the earliest period presented using a modified retrospective approach. Public business entities should apply
the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal
years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. We are
currently continuing to evaluate the impact of our pending adoption of ASU 2016-02 on our consolidated financial statements
In
May 2017 the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. ASU
2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply
modification accounting in Topic 718. ASU No. 2017-09 is effective for financial statements issued for annual reporting periods
beginning after December 15, 2017 and interim periods within those years. Earlier application was permitted. The adoption of the
new requirements of ASU No. 2017-09 did not have a material impact on the Company’s consolidated financial position or results
of operations
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
3:-
|
PREPAID
EXPENSES AND OTHER RECEIVABLES
|
|
|
December
31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Prepaid
expenses
|
|
$
|
42
|
|
|
$
|
45
|
|
Other
accounts receivable
|
|
|
49
|
|
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
91
|
|
|
$
|
56
|
|
|
|
December
31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Raw
materials
|
|
$
|
110
|
|
|
$
|
68
|
|
Work
in process
|
|
|
13
|
|
|
|
-
|
|
Finished
goods
|
|
|
21
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
144
|
|
|
$
|
76
|
|
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
5:-
|
PROPERTY
AND EQUIPMENT, NET
|
|
|
December
31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Cost:
|
|
|
|
|
|
|
|
|
Computers
and peripheral equipment
|
|
$
|
55
|
|
|
$
|
47
|
|
Office
furniture and equipment
|
|
|
3
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
|
|
50
|
|
Accumulated
depreciation:
|
|
|
|
|
|
|
|
|
Computers
and peripheral equipment
|
|
|
48
|
|
|
|
42
|
|
Office
furniture and equipment
|
|
|
2
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(50
|
)
|
|
|
(
45
|
)
|
|
|
|
|
|
|
|
|
|
Depreciated
cost
|
|
$
|
8
|
|
|
$
|
5
|
|
Depreciation
expenses for the years ended December 31, 2018 and 2017 were $6 and $7, respectively.
NOTE
6:-
|
OTHER
ACCOUNTS PAYABLE
|
|
|
December
31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Employees
and payroll accruals
|
|
$
|
204
|
|
|
$
|
219
|
|
Accrued
expenses
|
|
|
123
|
|
|
|
150
|
|
Income
tax accrual
|
|
|
120
|
|
|
|
260
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
447
|
|
|
$
|
629
|
|
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
7:-
|
CONVERTIBLE
PROMISSORY NOTES
|
Since
March 1, 2017 through September 30, 2017, the Company completed a series of bridge financings pursuant
to which the Company has received from accredited investors $1,380 of loans and issued to the investors
convertible promissory notes (the “2017 Notes”) in the aggregate principal amount of $1,380,
and seven-year warrants (the “Warrants”) to purchase an aggregate of 552,000 shares of
common stock at an exercise price of $5.90 per share.
The
2017 Notes accrued interest at a rate of 6% per annum, payable on the earlier of a 5-year anniversary of the issuance
date, or the date that the Company completes a Qualified Financing, as defined in the agreement (the “Maturity Date”).
To the extent not previously converted, on the Maturity Date, each investor had the right to receive, at the option of
the investor, either (a) cash equal to the original principal amount of the 2017 Notes and interest then accrued and unpaid
thereon, or (b) shares of common stock or Series C Convertible Preferred Stock of the Company, at a price per share equal
to the lesser of: (x) 80% of the amount equal to the quotient obtained by dividing (i) the estimated value of the Company
as of the Maturity Date, as determined in good faith by the Company’s board of directors, by (ii) the aggregate
number of outstanding shares of the Company’s common stock, as of the Maturity Date on a fully diluted basis, and
(y) $5.90 per share, as such amount may be adjusted for any stock split, stock dividend, reclassification or similar events
affecting the capital stock of the Company. Upon consummation of a Qualified Financing, the investors may elect to have
the outstanding principal and accrued but unpaid interest thereon converted into shares of the same class and series of
equity securities sold in such Qualified Financing, provided that the investor may elect to receive shares of Series C
Convertible Preferred Stock instead of shares of common stock, to the extent that common stock are issued in such Qualified
Financing, at a price per share equal to the lesser of: (a) 80% of the price per share at which such securities are sold
in such Qualified Financing and (b) $5.90 per share, as such amount may be adjusted for any stock split, stock dividend,
reclassification or similar events affecting the Company’s capital stock.
As
a result of issuing the warrants and as a result of the discount on the conversion price of the 2017 Notes, the Company
amortized the embedded benefit in the amount of $1,197 in the year ended December 31, 2017.
In
September 2017, all of the holders of the 2017 Notes agreed to convert the full principal and accrued interest on the
2017 Notes into equity securities of the Company in the event the Company consummated a Qualified Financing anytime before
December 31, 2017.
|
On
November 6, 2017, the Company completed a public offering, which constituted a Qualified Financing, upon which the 2017 Notes
were automatically converted. Based on the outstanding principal amount and all accrued but unpaid interest on the 2017 Notes,
at 80% of the offering price of $4.90 per share of common stock and accompanying warrant, the Company issued an aggregate of 361,462
shares of common stock (and common stock equivalents) and warrants to purchase an aggregate of 271,096 shares of common stock
to the holders of the 2017 Notes, all of which are subject to lock-up agreements for 180 days from November 1, 2017.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
8:-
|
COMMITMENTS
AND CONTINGENT LIABILITIES
|
|
a.
|
The
Company leases office facilities and motor vehicles under operating leases, which expire on various dates, the latest of which
is 2020.
|
Year
ended December 31,
|
|
Operating
leases
|
|
|
|
|
|
2019
|
|
$
|
43
|
|
2020
|
|
$
|
29
|
|
Total
|
|
$
|
72
|
|
The
Company leases motor vehicles under cancelable lease agreements. The Company has an option to be released from this lease agreement,
which may result in penalties in a maximum amount of approximately $5.
Rent
and related expenses were $31 and $27 for the years ended December 31, 2018 and 2017, respectively.
Motor
vehicle leases, and related expenses were $42 and $15 for the years ended December 31, 2018 and 2017, respectively.
|
b.
|
Royalties
to the Israel Innovation Authority (“the IIA”):
|
Under
the Company’s subsidiary research and development agreements with the IIA and pursuant to applicable laws, the Company is
required to pay royalties at the rate of 3-3.5% of sales of products developed with funds provided by the IIA, up to an amount
equal to 100% of the IIA research and development grants received, linked to the dollar including accrued interest at the LIBOR
rate. The Company has received through the years grants in the amount of $ 437. The Company is obligated to repay the Israeli
Government for the grants received only to the extent that there are sales of the funded products. As of December 31, 2018, there
are no sales from the funded projects.
As
of December 31, 2018, the Company has a contingent obligation to pay royalties in the principal amount of approximately $ 470.
In addition, the IIA may impose certain conditions on any arrangement under which it permits the Company to transfer technology
or development out of Israel.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY)
|
The
Common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company,
and the right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the
Company in the event of liquidation, dissolution or winding up of the Company.
|
b.
|
Series
C Preferred Stock:
|
Each
share of Series C Preferred stock is convertible into one share of Common stock (subject to adjustment) at any time at the option
of the holders, provided that each holder would be prohibited from converting Series C Preferred stock into shares of Common stock
if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number
of shares of Common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s
provision of not less than 61 days’ prior written notice to the Company.
In
the event of liquidation, dissolution, or winding up, each holder of Series C Preferred stock could elect to receive either (i)
in preference to any payments made to the holders of Common stock and any other junior securities, a payment for each share of
Series C Preferred stock then held equal $ 0.001, plus an additional amount equal to any dividends declared but unpaid on such
shares, and any other fees or liquidated damages then due and owing thereon or (ii) the amount of cash, securities or other property
to which such holder would be entitled to receive with respect to each share of Series C Preferred stock if such share of Series
C Preferred stock had been converted to Common stock immediately prior to such liquidation, dissolution, or winding up (without
giving effect to any conversion limitations).
Shares
of Series C Preferred stock are not entitled to receive any dividends, unless and until specifically declared by the board of
directors. However, holders of Series C Preferred stock are entitled to receive dividends on shares of Series C Preferred stock
equal (on an as-if-converted-to-Common-stock basis) to and in the same form as dividends actually paid on shares of the Common
stock when such dividends are specifically declared by the board of directors. The Company is not obligated to redeem or repurchase
any shares of Series C Preferred stock. Shares of Series C Preferred stock are not otherwise entitled to any redemption rights,
or mandatory sinking fund or analogous fund provisions.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
Each
holder of Series C Preferred stock is entitled to the number of votes equal to the number of whole shares of Common stock into
which the shares of Series C Preferred stock held by such holder are then convertible (subject to the beneficial ownership limitations)
with respect to any and all matters presented to the stockholders for their action or consideration. Holders of Series C Preferred
stock vote together with the holders of Common stock as a single class, except as provided by law and except that the consent
of holders of a majority of the outstanding Series C Preferred stock is required to amend the terms of the Series C Preferred
stock.
|
c.
|
Series
D Preferred Stock:
|
Each
share of Series D Preferred Stock is convertible into 1,000 shares of common stock (subject to the beneficial ownership limitations
and adjustment as provided in the certificate of designation) at any time at the option of the holders, provided that each holder
would be prohibited from converting Series D Preferred Stock into shares of common stock if, as a result of such conversion, any
such holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued
and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%,
provided that any increase in such percentage shall not be effective until the 61st day after such notice to the Company.
In
the event of our liquidation, dissolution, or winding up, each holder of Series D Preferred Stock will be entitled to receive
the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares
of Series D Preferred Stock if such shares had been converted to common stock immediately prior to such event (without giving
effect for such purposes to the 4.99% or 9.99% beneficial ownership limitation, as applicable) subject to the preferential rights
of holders of any class or series of the Company’s capital stock specifically ranking by its terms senior to the Preferred
D stock as to distributions of assets upon such event, whether voluntarily or involuntarily.
Shares
of Series D Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the board of
directors. However, holders of Series D Preferred Stock are entitled to receive dividends on shares of Series D Preferred Stock
equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of the common
stock when such dividends are specifically declared by the board of directors, except for stock dividends or distributions payable
in shares of common stock on shares of common stock or any other common stock equivalents for which the conversion price will
be adjusted. The Company is not obligated to redeem or repurchase any shares of Series D Preferred Stock. Shares of Series D Preferred
Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provision.
The
holders of the Series D Preferred Stock have no voting rights, except as required by law. The Company may not alter or change
adversely the powers, preferences and rights of the Series D Preferred Stock or amend the certificate of designation or amend
its certificate of incorporation or bylaws in any manner that adversely affects any right of the holders of the Series D Preferred
Stock without the affirmative vote of the holders of a majority of the shares of Series D Preferred Stock then outstanding.
The
Company is obligated to deliver shares of common stock upon conversion of the Series D Preferred Stock (the “Conversion
Shares”), within the time period specified in the certificate of designation. Failure to comply with the timely delivery
requirement triggers certain liquidated damages payable by the Company to each of the Series D Preferred Stock holders.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
If,
at any time while the Series D Preferred Stock is outstanding, the Company completed a Fundamental Transaction (as defined in
the certificate of designation), then upon any subsequent conversion of the Series D Preferred Stock, the holder will receive,
for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental
Transaction, the number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional cash, securities and/or other property or consideration (the “Alternate Consideration”)
receivable by holders of common stock as a result of such Fundamental Transaction for each share of common stock for which this
Series D Preferred Stock is convertible immediately prior to such Fundamental Transaction. For purposes of any such conversion,
the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
amount of Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction. If holders
of common stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series D Preferred
Stock following such Fundamental Transaction. If such Fundamental Transaction is also a Change of Control Transaction in which
the Company is not the surviving entity, then all shares of Series D Preferred Stock shall, upon consummation of such Change of
Control Transaction, automatically be converted into Conversion Shares.
Since
the Company has sufficient authorized and unissued shares available to settle its commitments and since all holders of equally
(both preferred stock and common stock) would receive the same form of consideration upon the consummation of a Fundamental Transaction,
and the shares are not otherwise redeemable, the shares of Series D Preferred Stock are classified within permanent equity, consistent
with the guidance of ASC 480.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
|
d.
|
In
April 2017, the Company issued 9,000 restricted shares of Common stock to a consultant as part of the total consideration
for its services associated with the Company’s investor relation services. The restricted shares were fully vested during
the year ended December 31, 2017. The stock based expense recognized in the financial statements for services received from
the consultant in the year ended December 31, 2017 amounted to $49.
|
|
|
|
|
e.
|
On
October 4, 2017, the Company issued 358,995 shares of Series C Preferred stock, to the holders of certain warrants to purchase
an aggregate of 563,910 shares of common stock that contained full ratchet anti-dilution price protection in such warrants
pursuant to a cashless exercise of such warrants.
|
|
|
|
|
f.
|
On
November 2, 2017, the Company issued 20,987 shares of common stock and 172,886 shares of Series C Preferred Stock to the
holders of certain warrants to purchase an aggregate of 299,733 shares of common stock pursuant to a cashless exercise
of such warrants.
|
|
g.
|
On
November 6, 2017, the Company closed the Offering of 897,958 shares of the Company’s common stock, 327 shares of
the Company’s Series D Preferred shares of the Company’s common stock (and common stock equivalents) at an
offering price of $4.90 per share of common stock, and $0.049 per share of Series D Preferred stock, and accompanying
warrant to purchase 0.75 of one share of common stock. Total gross proceeds from the offering totaled approximately $6,000,
and net proceeds of approximately $5,056 after deducting underwriting and estimated offering expenses. Each warrant has
an exercise price of $6.95 per full share of common stock with a life term of five years. The securities were issued pursuant
to the Company’s registration statement on Form S-1 originally filed with the Securities and Exchange Commission
on June 21, 2017, and declared effective on November 1, 2017.
|
|
h.
|
Starting
from March 1, 2017 through September 30, 2017, the Company completed a series of bridge financings pursuant to which the Company
have received from accredited investors aggregate proceeds of $1,380 in exchange for 2017 Notes in the aggregate principal
amount of $1,380, and seven-year Warrants to purchase an aggregate of 552,000 shares of common stock at an exercise price
of $5.90 per share. Upon closing of the Offering, the 2017 Notes were automatically converted and as a result the Company
issued an aggregate of 230,680 shares of common stock (and common stock equivalents), 131 shares of the Company’s Series
D preferred stock and warrants to purchase an aggregate of 271,096 shares of common stock.
|
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
|
|
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
|
|
|
|
i.
|
Warrants
issued to investors:
|
|
|
|
|
|
The
following table below summarizes the outstanding warrants issued to investors as of December 31, 2018 and 2017, respectively:
|
|
|
Warrants
outstanding as of December 31,
|
|
|
|
|
|
|
|
|
2018
|
|
|
2017
|
|
|
Exercise
price
|
|
|
Expiration
date
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November
2011 Warrants (1) (2)
|
|
|
—
|
|
|
|
245,893
|
|
|
|
1.393
|
|
|
November
15, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
February
2015 Warrants (3)
|
|
|
686,667
|
|
|
|
686,667
|
|
|
|
3.00/6.00
|
|
|
February
30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March
through September 2017 Warrants (5)
|
|
|
552,000
|
|
|
|
552,000
|
|
|
|
5.90
|
|
|
May
through September 2022
|
November
2017 Warrants (6)
|
|
|
1,296,605
|
|
|
|
1,250,687
|
|
|
|
6.90
|
|
|
November
1, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
outstanding
|
|
|
2,535,272
|
|
|
|
2,735,427
|
|
|
|
|
|
|
|
|
1.
|
In
November 2011, the Company issued to some of its stockholders warrants to purchase 2,319,062 shares of Series B-2 Preferred
stock with a fixed exercise price of $ 0.199 per share (reflecting a 30% discount on the fair value of the Company’s
Preferred stock on that date). The warrants expire on November 15, 2018. On May 2014, the Company effected a reverse split
of the Company’s stock of seven to one. In addition, on April 2015 all of the Company’s B-2 warrants were reclassified
as warrants to common shares. As a result, these warrants have a fixed exercise price of $1.393 to purchase 331,293 shares
of Common Stock. During 2017, 85,400 of the Company’s B-2 Warrants were exercised. During 2018, an additional 68,799
B-2 Warrants were exercised and the remaining 177,094 B-2 Warrants expired.
|
|
2.
|
In
February 2013 through December 2014, the Company issued to some of its stockholders warrants to purchase 563,910 shares of
Common stock. The exercise price at which the warrant may be exercised is $ 2.66 per share, subject to adjustment for stock
splits, fundamental transactions or similar events. The warrants were to expire in February 2018 through December 2019, based
on the issuance date (see also Note 8a). On October 4, 2017, these warrants were cashless exercised (see also Note 10e).
|
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
|
3.
|
In
February 2015, the Company negotiated a securities purchase agreement which included warrants to purchase 840,000 shares
of Common stock. The exercise price at which the warrant may be exercised is $3 for 420,000 shares and $6 for 420,000
shares, subject to certain adjustments. The warrants to purchase the 840,000 shares were to expire by February 2017. However,
in January 2017, the Company agreed to extend the warrants to purchase the 840,000 shares by additional two years until
February 2019 pursuant to the Warrant Amendment. On November 2, 2017, 153,333 of such warrants were cashless exercised
(see also Note 10f).
|
|
4.
|
On
March 25, 2015, the Company issued warrants to purchase up to 61,000 shares of Common stock to a consultant as consideration
for the provision of guidance and assistance in connection with the filing of the Company’s Form 10 and becoming
a public reporting company. The warrants had an exercise price of $2.57 per share, subject to adjustment for stock splits,
fundamental transactions or similar events and were scheduled to expire on March 25, 2020. On November 2, 2017, these
warrants were cashless exercised (see also Note 10f).
|
|
5.
|
During
the period March 1, 2017 through September 30, 2017, the Company completed a series of bridge financings pursuant to which
the Company have received from accredited investors aggregate proceeds of $1,380 in exchange for 2017 Notes in the aggregate
principal amount of $1,380, and seven-year Warrants to purchase an aggregate of 552,000 shares of common stock at an exercise
price of $5.90 per share.
|
|
6.
|
In
conjunction with the Company’s Offering for the issuance of 1,224,488 shares of the Company’s Common stock, the
Company also issued warrants to purchase up to 918,366 shares of common stock. Additionally, the Company issued to the underwriters
a unit purchase option to purchase units at an exercise price equal to $6.125 pursuant to which an aggregate of 61,224 shares
and warrants to purchase 45,918 shares are issuable to the underwriters. Upon closing of the Offering, the 2017 Notes were
automatically converted and as a result the Company issued an aggregate of 361,462 shares of common stock (and common stock
equivalents) and warrants to purchase an aggregate of 271,096 shares of common stock. The warrants have an exercise price
of $6.90 per share, subject to adjustment for stock splits, fundamental transactions or similar events and shall expire on
November 1, 2022.
|
In
November 2004, the Board of Directors of the Company adopted a stock option plan (“the Plan”), according to which
options may be granted to employees, directors and consultants.
Pursuant
to the Plan, the Company reserved for issuance 400,000 shares of Common stock. Each option entitles the holder to purchase one
share of Common stock of the Company and expires after 10 years from the date of grant. Any options that are terminated, cancelled,
forfeited or not exercised, become available for future grants.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
In
February 2014, the Board of Directors of the Company adopted a new stock option plan (“the New Plan”), according to
which options may be granted to employees, directors and consultants.
Pursuant
to the New Plan, the Company reserved for issuance 714,286 shares of Common stock. Each option entitles the holder to purchase
one share of Common stock of the Company and expires after 10 years from the date of grant. Any options that are terminated, cancelled,
forfeited or not exercised, become available for future grants.
|
On
June 13, 2018 the Company’s shareholders amended the NanoVibronix 2014 Long-Term Incentive Plan (the “2014
Plan”), to increase the aggregate number of shares of common stock reserved for issuance under the 2014 Plan by
an additional 750,000 shares, to a total of 1,464,286 shares (the “Plan Amendment Proposal”).
|
As
of December 31, 2018, under the New Plan, 292,737 options were available for future grants.
In
addition, the Company issued options to purchase 275,038 shares of Common Stock outside of the New Plan.
|
1.
|
Option
issued to employees, consutants and directors
|
A
summary of the Company’s options activity and related information with respect to options granted to employees,
consultants, and directors during the years ended December 31, 2018 and 2017 are as follows:
|
|
Number of
options
|
|
|
Weighted
average
exercise
price
|
|
|
Weighted
average
remaining
contractual life
|
|
|
Aggregate
intrinsic
value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding - January 1, 2017
|
|
|
1,234,934
|
|
|
$
|
3.01
|
|
|
|
7.18
|
|
|
|
3,419
|
|
2017 Activity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
—
|
|
|
$
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
$
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Expired or Forfeited
|
|
|
(7,160
|
)
|
|
$
|
10.08
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding - December 31, 2017
|
|
|
1,227,774
|
|
|
$
|
3.01
|
|
|
|
7.18
|
|
|
|
3,419
|
|
2018 Activity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
338,750
|
|
|
$
|
4.75
|
|
|
|
9.65
|
|
|
|
735
|
|
Exercised
|
|
|
(48,017
|
)
|
|
$
|
0.07
|
|
|
|
4.24
|
|
|
|
—
|
|
Expired or Forfeited
|
|
|
(71,920
|
)
|
|
$
|
4.41
|
|
|
|
7.16
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding - December 31, 2018
|
|
|
1,446,587
|
|
|
$
|
3.16
|
|
|
|
7.87
|
|
|
|
4,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at end of year - December 31, 2018
|
|
|
1,217,818
|
|
|
$
|
3.26
|
|
|
|
7.09
|
|
|
|
3,969
|
|
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
Weighted
average fair value of options granted to employees and directors during the years 2018 and 2017 was $ 2.17 and $ 0 per option,
respectively.
Aggregate
intrinsic value of unexercised options by employees and directors during the years 2018 and 2017 was $ 0. The
Aggregate intrinsic value of the unexercised options represents the total intrinsic value (the difference between the exercise
price and fair value at the time of measurement) multiplied by the number of options exercised.
The
aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s
closing share price on the last trading day of calendar 2018 and the exercise price, multiplied by the number of in-the-money
options) that would have been received by the option holders had all option holders exercised their options on December 31, 2018.
This amount is impacted by the changes in the fair market value of the Company’s shares.
As
of December 31, 2018, the total unrecognized estimated compensation cost related to non-vested options granted prior to that date
was $ 228 which is expected to be recognized over a weighted average period of approximately 2 years.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
9:-
|
STOCKHOLDERS’
EQUITY (DEFICIENCY) (Cont.)
|
|
3.
|
Total
stock-based compensation:
|
The
fair value for options granted in 2018 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with
the following underlying assumptions:
|
|
Year
ended
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Risk
free interest
|
|
|
2.77
|
%
|
|
|
—
|
|
Dividend yields
|
|
|
0
|
%
|
|
|
—
|
|
Volatility
|
|
|
54
|
%
|
|
|
—
|
|
Expected term (in
years)
|
|
|
5
|
|
|
|
—
|
|
The
Company applies ASC 505-50, “Equity-Based Payments to Non-Employees” (“ASC 505”) with respect to options
and warrants issued to non-employees which requires the use of option valuation models to measure the fair value of the options
and warrants at the measurement date.
The
total stock based expense recognized in the financial statements for services received from employees and non-employees is shown
in the following table (refer also to Note 10d):
|
|
Year ended
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Research and development
|
|
$
|
—
|
|
|
$
|
30
|
|
Selling and marketing
|
|
|
16
|
|
|
|
13
|
|
General and administrative
|
|
|
873
|
|
|
|
757
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
889
|
|
|
$
|
800
|
|
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
10:-
|
TAXES
ON INCOME
|
|
a.
|
As
of December 31, 2018, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately
$ 17,838. $3,441 of the federal net operating loss can be carried forward indefinitely and 14,397 of the federal net operating
losscan be offset against taxable income for 20 years. Utilization of the U.S. net operating losses may be subject to substantial
limitations in the event of a change of ownership provisions of the Internal Revenue Code of 1986.
|
|
|
|
|
b.
|
U.S.
Tax Cuts and Jobs Acts:
On
December 22, 2017, the U.S. Tax Cuts and Jobs Acts was enacted into law. The new legislation contains several key tax
provisions that will impact the Company. Changes include, but are not limited to, a corporate tax rate decrease from 35%
to 21% effective for tax years beginning after December 31, 2017, a one-time repatriation tax on accumulated foreign earnings,
a limitation on the tax deductibility of interest expense, an acceleration of business asset expensing, and a reduction
in the amount of executive pay that could qualify as a tax deduction. The lower corporate income tax rate will require
the Company to remeasure its U.S. deferred tax assets as well as reassess the realizability of its deferred tax assets.
ASC 740 requires the Company to recognize the effect of the tax law changes in the period of enactment. However, the SEC
staff has issued SAB 118 which allowed the Company to record provisional amounts during a measurement period.
The
Company has concluded that a reasonable estimate could be developed for the effects of the tax reform.
These effects,
which had an immaterial effect on the taxes on income due to the valuation allowance, have been included in the consolidated
financial statements for the year ended December 31, 2018.
|
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
10:-
|
TAXES
ON INCOME (Cont.)
|
|
1.
|
Tax
rates applicable to the income of the Israeli subsidiary:
|
|
|
The
Israeli corporate tax rate in 2018 and 2017 is 23% and 24%, respectively.
|
In
December 2017, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy
for the 2018 and 2017 Budget Years), 2017 which reduced the corporate income tax rate to 24% (instead of 25%) effective from January
1, 2017 and to 23% effective from January 1, 2018.
|
2.
|
The
subsidiary has final tax assessments through 2012.
|
|
d.
|
Loss
before taxes on income:
|
|
|
|
Year
ended
December 31,
|
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
|
Domestic
|
|
|
$
|
3,503
|
|
|
$
|
4,930
|
|
Foreign
|
|
|
|
779
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
4,282
|
|
|
$
|
4,927
|
|
|
e.
|
Deferred
income taxes:
|
Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as
follows:
|
|
|
December
31,
|
|
|
|
|
2018
|
|
|
2017
|
|
Deferred
tax assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
operating loss carry forward
|
|
|
$
|
3,746
|
|
|
$
|
2,722
|
|
Temporary
differences
|
|
|
|
35
|
|
|
|
35
|
|
Deferred
tax assets before valuation allowance
|
|
|
|
3,781
|
|
|
|
2,757
|
|
Valuation
allowance
|
|
|
|
(3,781
|
)
|
|
|
(2,757
|
)
|
|
|
|
|
|
|
|
|
|
|
Net
deferred tax asset
|
|
|
$
|
—
|
|
|
$
|
—
|
|
For
the year ended December 31, 2018, the net change in valuation allowance of $1,024 was related to the increase in valuation
allowance included in the income tax provision. For the year ended December 31, 2017, the decrease in valuation allowance of
$1,171 was related to the change in valuation allowance due to a $1,571 reduction due to reduced benefits from the reduction
of the corporate tax rates from 35% to 21% offset by an $400 increase in valuation allowance included in the income tax
provision.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
10:-
|
TAXES
ON INCOME (Cont.)
|
In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion
of the deferred tax assets will not be realized.
The
ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in
which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the
Company recorded a full valuation allowance at December 31, 2018 and 2017.
|
f.
|
Reconciliation
of the theoretical tax expense to the actual tax expense:
|
The
main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax
benefits from accumulated net operating loss carryforward among the Company and its subsidiary due to the uncertainty of the realization
of such tax benefits.
|
g.
|
A
reconciliation of the beginning and ending balances of uncertain tax benefits is as follows:
|
|
|
|
December
31,
|
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
|
Balance
at beginning of the year
|
|
|
$
|
168
|
|
|
$
|
170
|
|
Increases
related to tax positions from prior years
|
|
|
|
—
|
|
|
|
17
|
|
Lapses
of statutes of limitation
|
|
|
|
(
168
|
)
|
|
|
(19)
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at the end of the year
|
|
|
$
|
—
|
|
|
$
|
168
|
|
The
Company recognizes interest and penalties related to unrecognized tax benefits in tax expense. During the year ended December
31, 2018, the Company accrued $0 for interest and penalties expenses related to uncertain tax positions.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
|
NOTE
11:-
|
FINANCIAL
INCOME (EXPENSE), NET
|
|
|
Year
ended
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Interest
on promissory notes
|
|
$
|
—
|
|
|
$
|
(37)
|
|
Discount
amortization of promissory notes
|
|
|
—
|
|
|
|
(1,197)
|
|
Change
in fair value of warrants
|
|
|
—
|
|
|
|
(549)
|
|
Other
financial income (expense)
|
|
|
22
|
|
|
|
(53)
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
22
|
|
|
$
|
(1,836)
|
|
|
NOTE
12:-
|
GEOGRAPHIC
INFORMATION AND MAJOR CUSTOMER DATA
|
Summary
information about geographic areas:
ASC
280, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments
are defined as components of an enterprise about which separate financial information is available that is evaluated regularly
by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages
its business on the basis of one reportable segment, and derives revenues from selling its products mainly through distributor
agreements. The following is a summary of revenues within geographic areas:
|
|
Year
ended
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
United
States
|
|
$
|
164
|
|
|
$
|
90
|
|
Israel
|
|
|
49
|
|
|
|
8
|
|
United
Kingdom
|
|
|
50
|
|
|
|
74
|
|
European
Union (excluding United Kingdom)
|
|
|
8
|
|
|
|
14
|
|
India
|
|
|
17
|
|
|
|
14
|
|
Other
|
|
|
30
|
|
|
|
39
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
318
|
|
|
$
|
239
|
|
During
the year ended December 31, 2018, there were sales to two distributors each of which accounted for approximately 22% of total
sales. During the year ended December 31, 2017, there were sales to two distributors each of which accounted for approximately
11% of total sales.
The
Company’s long-lived assets are all located in Israel.
NANOVIBRONIX INC. AND ITS SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 13:-
|
RELATED PARTIES BALANCES AND TRANSACTIONS
|
Financial expenses – related
part convertible note:
During the
period ended December 31, 2017, the Company incurred $549 in financial expenses associated with the issuance of convertible notes
to related party lenders (Refer to footnote 7 for more information).
Exchange of common stock for
Preferred C stock:
In 2018,
the Company exchanged 250,000 shares of common stock for 250,000 shares of Preferred C stock with a significant shareholder. The
significant shareholder has the right to exchange an additional 50,000 common shares at their discretion.
Board members resignation and
severance agreement:
On July
4, 2018, Jona Zumeris, Vice President of Technology and member of the board of directors of NanoVibronix, Inc. and the Company’s
subsidiary, submitted his resignation.
On July
4, 2018, the Company and Dr. Zumeris and his wife, Janina (Ina) Zumeris entered into a Separation and Release Agreement (the “Separation
Agreement”), providing that Dr. Zumeris shall resign from all positions at the Company and that Dr. Zumeris and Janina Zumeris
will cooperate with the Company and its officers on meeting certain technical and administrative milestones during the transition
period ending 60 days following the date of the Separation Agreement (the “Termination Date”). If Dr. Zumeris and Janina
Zumeris have met such milestones to the satisfaction of the Company and fulfilled other obligations under the Separation Agreement,
(i) Dr. Zumeris and Janina Zumeris, will be entitled to receive as consulting payments an aggregate of approximately $18,000 per
month for 12 months, commencing 30 days after the Termination Date; (ii) the Company’s management, beginning on November
4, 2018, will use its best efforts to allow the sale of the Company’s securities owned by Dr. Zumeris, provided that such
sale would be in compliance with the applicable U.S. securities laws and regulations, and provided further, that, if the Company’s
shares of common stock held by Dr. Zumeris had not been sold at a price lower than $4.45 during the fourteen month period from
July 4, 2018, and the value of the unsold securities Dr. Zumeris owns plus the value of cash received by Dr. Zumeris from the sale
of the Company’s securities during such fourteen month period (the “Aggregate Amount”), in aggregate, is less
than $950,000, then the Company will make up the difference between $950,000 and the Aggregate Amount by extending the term of
engagement of Dr. Zumeris and Janina Zumeris’s consulting services. In addition, if the Company (i) grants a license for
the skin rejuvenation technology, then the Company will pay Dr. Zumeris 10% from the payments received by the Company until an
aggregate amount of $100,000 has been paid to Dr. Zumeris, (ii) sells the skin rejuvenation technology and/or the rights to such
as a standalone product, the Company will pay Dr. Zumeris $100,000 from the proceeds of such sale, or (iii) sells the skin rejuvenation
devices, the Company will pay Dr. Zumeris $5 per unit an aggregate amount of $100,000 has been paid to Dr. Zumeris.
NANOVIBRONIX INC. AND ITS SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
U.S. dollars in thousands (except share and per share data)
|
NOTE 13:-
|
RELATED PARTIES BALANCES AND TRANSACTIONS (Cont.)
|
In
connection with the Company’s agreement with Dr. Zumeris, the Company was to evaluate if any liability should be accrued
for each reporting period. As of December 31, 2018, Dr. Zumeris exercised options under $4.45 a share and therefore the Company
will not need to record a liability for this transaction.
During
the year ended December 31, 2018, The Company incurred expenses of $108 associated with this agreement.
All
outstanding share options and warrants for the year ended December 31, 2018 and 2017 have been excluded from the
calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods
presented.
The
following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:
|
|
December
31,
2018
|
|
|
December
31,
2017
|
|
Series
D Preferred Shares
|
|
|
303,782
|
|
|
|
303,782
|
|
Stock
Options – employee and non-employee
|
|
|
734,756
|
|
|
|
812,773
|
|
Warrants
|
|
|
266,667
|
|
|
|
512,560
|
|
Total
|
|
|
1,305,205
|
|
|
|
1,629,115
|
|
NOTE
15:
|
SUBSEQUENT
EVENTS
|
On
February 5, 2019, the Company entered into amendments to its two-year warrants (the “Warrant Amendment”) to purchase
an aggregate of 420,000 shares of common stock at an exercise price of $3.00 per share (the “$3.00 Warrants”) and
warrants to purchase an aggregate of 420,000 shares of common stock at an exercise price of $6.00 per share (the “$6.00
Warrants”), issued in January and February 2015, to extend the expiration date of the warrants for two additional years.
In addition, the Warrant Amendment amended the exercise price with respect to the $3.00 Warrants from $3.00 per share to $3.35
per share. The exercise price of the $6.00 Warrants was unchanged. Pursuant to the Warrant Amendment, warrants to purchase 266,667
shares of common stock at $3.35 per share and warrants to purchase 266,667 shares of common stock at $6.00 per share will expire
on January 29, 2021, and the warrants to purchase 140,000 shares of common stock at $3.35 per share and warrants to purchase 140,000
shares of common stock at $6.00 per share will expire on February 10, 2021, and the warrants to purchase 13,333 shares of common
stock at $3.35 per share and warrants to purchase 13,333 shares of common stock at $6.00 per share will expire on February 23,
2021. The Warrant Amendment is effective as of January 29, 2019. All other terms of the original warrants remain the same.
Holders
of the warrants who entered into the amendment with the Company include the following affiliates of the Company: (i) a subsidiary
of IDT Corporation, a greater than five percent stockholder of the Company, who holds warrants to purchase 266,667 shares of common
stock at $3.35 per share and warrants to purchase 266,667 shares of common stock at $6.00 per share, and (ii) entities controlled
by Mr. Paul Packer and Mr. Packer, a greater than five percent stockholder of the Company, who holds warrants to purchase 66,666
shares of common stock at $3.35 per share and warrants to purchase 66,666 shares of common stock at $6.00 per share.
NANOVIBRONIX
INC. AND ITS SUBSIDIARY
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Amounts in thousands (except share and per share data)
|
NOTE
15:
|
SUBSEQUENT
EVENTS (Cont.)
|
On
February 21, 2019, the Company entered into a consulting agreement (the “Agreement”) with Bespoke Growth Partners,
Inc. (“Bespoke”), pursuant to which Bespoke will provide the Company with consulting services with respect to, among
other things, advancement of the Company’s business plan, possible joint ventures, strategic alliances, mergers and acquisitions
and related development activities (the “Services”).
In
consideration for the Services, the Company paid Bespoke a cash fee of $50,000 and issued to Bespoke 275,000 shares of the Company’s
common stock upon signing the Agreement. In addition, if the Company has not previously terminated the Agreement, the Company
has agreed to issue Bespoke (i) an additional 75,000 shares of common ctock on the three (3) month anniversary of the Agreement,
(ii) an additional 200,000 shares of common stock on the seven (7) month anniversary of the Agreement, and (iii) an additional
100,000 shares of common stock on the ten (10) month anniversary of the Agreement. The Agreement contains a blocker provision
that prohibits the issuance of common stock to Bespoke during the term of the Agreement which would cause the beneficial ownership
of Bespoke and its affiliates to exceed 9.99% of the Company’s outstanding shares of common stock.
The
Agreement has an initial term of one (1) year, unless earlier terminated by the Company. The Company may terminate the Agreement
before the end of the initial term upon 30 calendar days’ notice to Bespoke. The Agreement provides for indemnification
of Bespoke, its officers, directors, members, employees, affiliates, and agents by the Company of all losses, expenses, damages
and costs, including reasonable attorneys’ fees, resulting from any act, action or omission, except for acts of Bespoke
of willful misconduct, bad faith or gross negligence related to the Agreement.
On March 29, 2019, the
Company completed a bridge financing, pursuant to which the Company issued to two accredited investors convertible notes on
the aggregate principal amount of $225,000 (the “Notes”) and seven-year warrants (the “Warrant”) to
purchase an aggregate of 90,000 shares of the Company’s common stock or series C preferred stock at an exercise price
of the
lesser
of: (a) 80% (
i.e
., a 20% discount) of the exercise price per share of the warrants to purchase
shares of the Company’s capital stock issued in the first equity financing of the Company following the date of
issuance, or (b) $4.80, with a stipulation that in no event will the exercise price be less than $3.00 per warrant share.
The principal amount and all accrued but unpaid interest on the Notes are due and payable on the
date (the “Maturity Date”) that is the earlier of the (i) 5-year anniversary of the date of issuance, or (ii) the date
the Company completes an equity financing pursuant to which the Company issues and sells shares of capital stock resulting in aggregate
proceeds of at least $2,000,000 (a “Qualified Financing”). The Notes bear interest at a rate of 6% per annum, payable
on the Maturity Date. To the extent not previously converted, on the Maturity Date, the investors will receive, at the option of
each the investor, either (a) cash equal to the original principal amount of the Note and interest then accrued and unpaid thereon,
or (b) shares of common stock or series C convertible preferred stock of the Company, at a price per share equal to the lesser
of: (x) 80% of the amount equal to the quotient obtained by dividing (i) the estimated value of the Company as of the Maturity
Date, as determined in good faith by the Company’s board of directors, by (ii) the aggregate number of outstanding shares
of the Company’s common stock, as of the Maturity Date on a fully diluted basis, and (y) $4.00 per share, as such amount
may be adjusted for any stock split, stock dividend, reclassification or similar events affecting the capital stock of the Company.
Upon consummation of a Qualified Financing, each investor may elect to have the outstanding principal and accrued but unpaid interest
thereon converted into (a) shares of the same class and series of equity securities sold in such Qualified Financing, (b) shares
of series C convertible preferred stock or (c) common stock, at a price per share equal to the lesser of: (a) 80% of the price
per share at which such securities are sold in such Qualified Financing and (b) $4.00 per share, as such amount may be adjusted
for any stock split, stock dividend, reclassification or similar events affecting the Company’s capital stock.
In
no event will the number of shares to be issued upon (i) exercise of this Warrants, (ii) conversion of the Notes exceed, in the
aggregate, 9.9% of the total shares outstanding or the voting power outstanding on the date immediately preceding the date of issuance.